Search Result

Results for "

Prostate+Hyperplasia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5 alpha Reductase (13) Adrenergic Receptor (42) Akt (1) Androgen Receptor (5) Apoptosis (5) Biochemical Assay Reagents (1) Drug Derivative (1) Endogenous Metabolite (6) Environmental Pollutants (1) GnRH Receptor (1) Histamine Receptor (1) Isotope-Labeled Compounds (12) LPL Receptor (1) Phosphodiesterase (PDE) (2) Reference Standards (11)
By Research Areas:	Cancer (24) Cardiovascular Disease (11) Endocrinology (42) Infection (1) Inflammation/Immunology (2) Metabolic Disease (12) Neurological Disease (7)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13635

Finasteride 4 Publications Verification MK-906	Environmental Pollutants 5 alpha Reductase	Cancer
Finasteride (MK-906) is an orally active and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

HY-B0661

Tamsulosin 2 Publications Verification (R)-(-)-YM12617 free base; LY253351 free base	Adrenergic Receptor Apoptosis	Neurological Disease Endocrinology Cancer
Tamsulosin ((R)-(-)-YM12617 free base) is an orally active antagonist of α₁-adrenergic receptor. Tamsulosin induces Apoptosis. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models .

HY-B0371F

Terazosin hydrochloride Maximum Cited Publications 7 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0661A

Tamsulosin hydrochloride 2 Publications Verification (R)-(-)-YM12617; LY253351	Adrenergic Receptor Apoptosis	Neurological Disease Endocrinology Cancer
Tamsulosin hydrochloride ((R)-(-)-YM12617 free base) is an orally active antagonist of α₁-adrenergic receptor. Tamsulosin hydrochloride induces Apoptosis. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models .

HY-B0192

Alfuzosin 1 Publications Verification SL 77499	Adrenergic Receptor	Endocrinology
Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .

HY-B0371

Terazosin Maximum Cited Publications 7 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-107385

Epristeride 3 Publications Verification ONO-9302; SKF105657	5 alpha Reductase	Cancer
Epristeride (ONO-9302) is a selective, specific and orally active uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. Epristeride has inhibitory effects for SR isoenzymes types 2 with K_i value of 0.7-2 nM. Epristeride can be used for the research of prostatic hyperplasia and acne .

HY-B0371A

Terazosin hydrochloride dihydrate Maximum Cited Publications 7 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0391

Naftopidil 1 Publications Verification KT-611; BM-15275	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia .

HY-B0192A

Alfuzosin hydrochloride 1 Publications Verification SL 77499-10	Adrenergic Receptor	Endocrinology
Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .

HY-115450

ONO-0300302	LPL Receptor	Endocrinology Cancer
ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC₅₀ of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with K_d of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research .

HY-P3501

Fexapotide NX-1207	Apoptosis	Cancer
Fexapotide (NX-1207) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

HY-158498

FA2 glycan (G0F) FA2 N-linked oligosaccharide; F(6)A2 glycan	Biochemical Assay Reagents	Cancer
FA2 glycan (G0F) (FA2 N-linked oligosaccharide; F(6)A2 glycan) is a core-fucosylated biantennary N-linked oligosaccharide that serves as a prostate cancer biomarker. The level of FA2 glycan (G0F) is higher in prostate cancer than in benign prostatic hyperplasia, and it is further elevated in advanced prostate cancer with a Gleason score ≥8 compared with both benign prostatic hyperplasia and low-/intermediate-risk prostate cancer. FA2 glycan (G0F) can be used in prostate cancer research .

HY-103204

RS100329 hydrochloride	Adrenergic Receptor	Endocrinology
RS100329 hydrochloride is a potent and selective α1A-adrenoceptor antagonist with pK_i values of 9.6, 7.9 and 7.5 for α1A, α1D, and α1B, respectively. RS100329 hydrochloride inhibits reflex urethral contractions. RS100329 hydrochloride can be used in research of benign prostatic hyperplasia .

HY-N8850

Angelol G	Others	Cancer
Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC₅₀ value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .

HY-12718

(±)-WB 4101	Adrenergic Receptor	Cardiovascular Disease
(±)-WB 4101 is a highly selective α1-adrenergic receptor antagonist. (±)-WB 4101 blocks norepinephrine-induced vascular smooth muscle contraction to exert antihypertensive and benign prostatic hyperplasia (BPH)-relieving effects. (±)-WB 4101 is promising for research of hypertension and BPH .

HY-B0371S

Terazosin-d8	Isotope-Labeled Compounds Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-13635A

Finasteride acetate MK-906 acetate	5 alpha Reductase	Cancer
Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

HY-13635R

Finasteride (Standard) MK-906 (Standard)	Reference Standards 5 alpha Reductase	Cancer
Finasteride (Standard) is the analytical standard of Finasteride. This product is intended for research and analytical applications. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

HY-19144

ONO-3805	5 alpha Reductase	Others
ONO-3805 is an early lead compound of a non-steroidal 5α-reductase inhibitor, used to inhibit the conversion of testosterone to dihydrotestosterone, with potential effects in inhibiting benign prostatic hyperplasia.

HY-105173

Teverelix EP 24332	GnRH Receptor Histamine Receptor	Endocrinology Cancer
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .

HY-106174

Lapisteride CS 891	5 alpha Reductase	Endocrinology
Lapisteride (CS 891) is an orally active 5α-reductase inhibitor. Lapisteride can inhibit 5α-reductaseactivity in the hair follicles (HF). Lapisteride can be used in prostatic hyperplasia and androgenic alopecia research .

HY-106363

MK-0963 L 654066	5 alpha Reductase	Others
MK-0963 is a steroidal 5α-reductase inhibitor. MK-0963 reduces serum dihydrotestosterone (DHT) concentrations in a dose-dependent manner. MK-0963 can be used for the study of dihydrotestosterone-related diseases such as benign prostate hyperplasia (BPH) .

HY-123323

MK-0434	5 alpha Reductase	Endocrinology
MK-0434 is an orally active steroid 5α-reductase inhibitor. MK-0434 specifically inhibits steroid 5α-reductase, thereby reducing the level of dihydrotestosterone (DHT) in the body. MK-0434 can be used in the study of benign prostatic hyperplasia .

HY-B0661AS1

Tamsulosin-d4 hydrochloride (R)-(-)-YM12617-d₄; LY253351-d₄	Isotope-Labeled Compounds Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology
Tamsulosin-d₄ (hydrochloride) is deuterium labeled Tamsulosin (hydrochloride). Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models .

HY-19268

GG-818 GW 1818	Adrenergic Receptor	Metabolic Disease
GG-818 (GW 1818) is a potent and selective α1 adrenoceptor antagonist, with pK_i values of 9.7 for α1_a, 7.8 for α1_b, and 7.6 for α1_d. GG-818 (GW 1818) can be used for benign prostatic hyperplasia research .

HY-17019

SL-89.0591	Adrenergic Receptor	Inflammation/Immunology
SL-89.0591 is a uroselective α1-adrenoceptor antagonist. SL-89.0591 exhibits a more potent blocking effect on urethral receptors than on vascular receptors in anesthetized rabbits, with a lower risk of orthostatic hypotension. SL-89.0591 can be used in research related to benign prostatic hyperplasia .

HY-B0192AR

Alfuzosin hydrochloride (Standard) SL 77499-10 (Standard)	Reference Standards Adrenergic Receptor	Endocrinology
Alfuzosin (hydrochloride) (Standard) is the analytical standard of Alfuzosin (hydrochloride). This product is intended for research and analytical applications. Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .

HY-106614

Osaterone acetate	Androgen Receptor 5 alpha Reductase	Endocrinology
Osaterone acetate is an orally active steroid anti-androgen agent, mainly used for benign prostatic hyperplasia (BPH) in dogs. Osaterone acetate competitively antagonizes androgen receptor and inhibits 5α-reductase, reducing the concentration of dihydrotestosterone (DHT) while blocking the growth-stimulating effects of testosterone and DHT on prostate cells. Osaterone acetate can rapidly alleviate the symptoms of BPH in dogs without affecting the fertility of breeding dogs .

HY-B0391A

Naftopidil dihydrochloride KT-611 dihydrochloride; BM-15275 dihydrochloride	Adrenergic Receptor	Cancer
Naftopidil dihydrochloride (KT-611 dihydrochloride) is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil dihydrochloride has antiproliferative effects. Naftopidil dihydrochloride can be used for the research of prostate hyperplasia .

HY-165478

FCE 28260	5 alpha Reductase	Endocrinology
FCE 28260 is an orally active 4-azacyclic 5α-reductase (5αR) inhibitor. FCE 28260 exhibits IC₅₀ values for human 5αR type 1 and 5αR type 2 of 36 and 3.3 nM, respectively, and for human and rat prostates with IC₅₀ values of 16 and 15 nM, respectively. FCE 28260 simultaneously blocks the production of dihydrotestosterone (DHT) in the prostate and peripheral tissues. FCE 28260 can significantly inhibit the induction of prostatic and seminal vesicle hyperplasia by testosterone (T) in rat models, without inhibiting the growth of the prostate in DHT implantation models. FCE 28260 can be used for the studies DHT-dependent diseases such as benign prostatic hyperplasia (BPH) .

HY-B0192AS

Alfuzosin-d3 hydrochloride SL 77499-10-d₃	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
Alfuzosin-d3 hydrochloride is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-B0192AS1

Alfuzosin-d7 hydrochloride SL 77499-10-d₇	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
Alfuzosin-d₇ (hydrochloride) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-103202

SNAP5089 hydrochloride	Adrenergic Receptor	Cardiovascular Disease
SNAP5089 (hydrochloride) is a selective α1A adrenergic receptor antagonist. SNAP5089 (hydrochloride) can be used in the research of hypertension and benign prostatic hyperplasia .

HY-134632

Dehydro silodosin KMD-3241	Adrenergic Receptor	Cancer
Dehydro silodosin (KMD-3241) is a selective α1A-adrenoceptor antagonist used in the study of benign prostatic hyperplasia .

HY-123710

GYKI-16084	Endogenous Metabolite	Others
GYKI-16084 is a new compound that can be isolated from dog and rat urine. GYKI-16084 can be used in the research of benign prostatic hyperplasia .

HY-P1442

AdTx1	Adrenergic Receptor	Cancer
AdTx1 is a selective α1A-adrenoceptor antagonist (K_i: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia .

HY-135473

Chlormadinone	Androgen Receptor	Metabolic Disease Endocrinology Cancer
Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia .

HY-105537

Ro 70‐0004 RS-100975	Adrenergic Receptor	Endocrinology
Ro 70-0004 (RS-100975) is a selective alpha1A-adrenoceptor antagonist with a pK_i of 8.9. Ro 70‐0004 can be used in the study of prostatic hyperplasia .

HY-P3501A

Fexapotide TFA NX-1207 TFA	Apoptosis	Cancer
Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

HY-105122

Zanoterone WIN 49596	Androgen Receptor	Endocrinology Cancer
Zanoterone is an orally active antagonist of the androgen receptor (AR) with a K_i of 2.2 μM. Zanoterone blocks the binding of androgens such as testosterone and dihydrotestosterone (DHT), inhibiting the androgen signaling pathway, thereby reducing androgen-dependent prostate hyperplasia and prostate cancer growth .

HY-101826A

ER21355 hydrochloride	Phosphodiesterase (PDE)	Cancer
ER21355 hydrochloride is the hydrochloride form of ER21355 (HY-101826). ER21355 hydrochloride is an inhibitor for phosphodiesterase (PDE), which is potent for ameliorating benign prostatic hyperplasia (BPH) and prostatism through increasing levels of cAMP and cGMP, and resulting a relaxation of the smooth muscle cell .

HY-Z12431

Silodosin carboxylic acid impurity KMD-3293	Endogenous Metabolite	Metabolic Disease
Silodosin carboxylic acid impurity (KMD-3293) is an inactive silodosin metabolite. Silodosin carboxylic acid impurity is the major metabolite that can be generated via oxidation by alcohol and aldehyde dehydrogenase. Silodosin carboxylic acid impurity can be studied in research for benign prostatic hyperplasia .

HY-135473S

Chlormadinone-d6	Isotope-Labeled Compounds Androgen Receptor	Metabolic Disease
Chlormadinone-d₆ is the deuterium labeled Chlormadinone (HY-135473). Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia .

HY-B0661AS

Tamsulosin-d5 hydrochloride (R)-(-)-YM12617-d₅; LY253351-d₅	Isotope-Labeled Compounds Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology
Tamsulosin-d₅ (hydrochloride) is the deuterium labeled Tamsulosin hydrochloride. Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models .

HY-135473R

Chlormadinone (Standard)	Androgen Receptor Reference Standards	Metabolic Disease
Chlormadinone (Standard) is the analytical standard of Chlormadinone (HY-135473). This product is intended for research and analytical applications. Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia .

HY-B0661R

Tamsulosin (Standard) (R)-(-)-YM12617 free base (Standard); LY253351 free base (Standard)	Reference Standards Adrenergic Receptor Endogenous Metabolite	Neurological Disease Endocrinology Cancer
Tamsulosin (Standard) is the analytical standard of Tamsulosin. This product is intended for research and analytical applications. Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of α₁-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models .

HY-B0192S

Alfuzosin-d7 SL 77499-d₇	Adrenergic Receptor	Endocrinology
Alfuzosin-d₇ is the deuterium labeled Alfuzosin . Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .

HY-B0192R

Alfuzosin (Standard) SL 77499 (Standard)	Adrenergic Receptor Reference Standards	Endocrinology
Alfuzosin (Standard) is the analytical standard of Alfuzosin. This product is intended for research and analytical applications. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .

HY-B0371FR

Terazosin hydrochloride (Standard)	Reference Standards Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin (hydrochloride) (Standard) is the analytical standard of Terazosin (hydrochloride). This product is intended for research and analytical applications. Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

Cat. No.	Product Name	Type

HY-158498

FA2 glycan (G0F)

FA2 N-linked oligosaccharide; F(6)A2 glycan

Biochemical Assay Reagents

FA2 glycan (G0F) (FA2 N-linked oligosaccharide; F(6)A2 glycan) is a core-fucosylated biantennary N-linked oligosaccharide that serves as a prostate cancer biomarker. The level of FA2 glycan (G0F) is higher in prostate cancer than in benign prostatic hyperplasia, and it is further elevated in advanced prostate cancer with a Gleason score ≥8 compared with both benign prostatic hyperplasia and low-/intermediate-risk prostate cancer. FA2 glycan (G0F) can be used in prostate cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P3501

Fexapotide NX-1207	Apoptosis	Cancer
Fexapotide (NX-1207) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

HY-105173

Teverelix EP 24332	GnRH Receptor Histamine Receptor	Endocrinology Cancer
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .

HY-P1442

AdTx1	Adrenergic Receptor	Cancer
AdTx1 is a selective α1A-adrenoceptor antagonist (K_i: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia .

HY-P3501A

Fexapotide TFA NX-1207 TFA	Apoptosis	Cancer
Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0661

Tamsulosin 2 Publications Verification (R)-(-)-YM12617 free base; LY253351 free base	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Endocrinology Source Classification Cancer	Adrenergic Receptor Apoptosis
Tamsulosin ((R)-(-)-YM12617 free base) is an orally active antagonist of α₁-adrenergic receptor. Tamsulosin induces Apoptosis. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models .

HY-B0661A

Tamsulosin hydrochloride 2 Publications Verification (R)-(-)-YM12617; LY253351	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Adrenergic Receptor Apoptosis
Tamsulosin hydrochloride ((R)-(-)-YM12617 free base) is an orally active antagonist of α₁-adrenergic receptor. Tamsulosin hydrochloride induces Apoptosis. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models .

HY-B0371

Terazosin Maximum Cited Publications 7 Publications Verification	Classification of Application Fields Disease Research Fields Endocrinology	Adrenergic Receptor
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-N8850

Angelol G	Leguminosae Campylotropis hirtella (Franch.) Schindl. Coumarins Phenylpropanoids Plants Source Classification	Others
Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC₅₀ value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .

HY-B0661R

Tamsulosin (Standard) (R)-(-)-YM12617 free base (Standard); LY253351 free base (Standard)	Structural Classification Alkaloids Other Alkaloids Endogenous metabolite Source Classification	Reference Standards Adrenergic Receptor Endogenous Metabolite
Tamsulosin (Standard) is the analytical standard of Tamsulosin. This product is intended for research and analytical applications. Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of α₁-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models .

HY-B0661AR

Tamsulosin hydrochloride (Standard) (R)-(-)-YM12617 (Standard); LY253351 (Standard)	Structural Classification Alkaloids Other Alkaloids Endogenous metabolite Source Classification	Reference Standards Adrenergic Receptor Apoptosis
Tamsulosin (hydrochloride) (Standard) is the analytical standard of Tamsulosin hydrochloride (HY-B0661A). Tamsulosin hydrochloride ((R)-(-)-YM12617 free base) is an orally active antagonist of α₁-adrenergic receptor. Tamsulosin hydrochloride induces Apoptosis. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models .

HY-W357141

Methyl 2-O-β-D-glucopyranosylbenzoate Methyl salicylate 2-O-β-D-glucopyranoside	Structural Classification Piperaceae Piper crocatum Ruiz & Pav. Plants Saccharides Monosaccharides Source Classification	Drug Derivative
Methyl 2-O-β-D-glucopyranosylbenzoate (Methyl salicylate 2-O-β-D-glucopyranoside) (Compound 11) is a phenolic compound. Methyl 2-O-β-D-glucopyranosylbenzoate can be isolated from the leaves of Metapanax delavayi. Methyl 2-O-β-D-glucopyranosylbenzoate has anti-benign prostatic hyperplasia activities and significantly inhibits the proliferation of BPH-1 cells. β-Phenylethyl β-D-glucoside can be used for prostatitis research .

HY-N13195

(15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one	Triterpenes Microorganisms Terpenoids Source Classification	5 alpha Reductase
(15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one shows a 5a-reductase inhibitory activity with an IC₅₀ value of 41.9 μM. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one inhibits the growth of the ventral prostate induced by testosterone in rat. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one is promising for research of benign prostatic hyperplasia (BPH) as well as other 5α-dihydrotestosterone (DHT)-related disorders, such as acne and male pattern baldness .

HY-N18683

Saw palmetto extract	Structural Classification Extract	Others
Saw palmetto extract can be used to study lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).

Cat. No.	Product Name	Chemical Structure

HY-B0371S

Terazosin-d8
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0661AS1

Tamsulosin-d4 hydrochloride
Tamsulosin-d₄ (hydrochloride) is deuterium labeled Tamsulosin (hydrochloride). Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models .

HY-B0192AS

Alfuzosin-d3 hydrochloride
Alfuzosin-d3 hydrochloride is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-B0192AS1

Alfuzosin-d7 hydrochloride
Alfuzosin-d₇ (hydrochloride) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).

HY-135473S

Chlormadinone-d6
Chlormadinone-d₆ is the deuterium labeled Chlormadinone (HY-135473). Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia .

HY-B0661AS

Tamsulosin-d5 hydrochloride
Tamsulosin-d₅ (hydrochloride) is the deuterium labeled Tamsulosin hydrochloride. Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models .

HY-B0192S

Alfuzosin-d7
Alfuzosin-d₇ is the deuterium labeled Alfuzosin . Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .

HY-B0661S

Tamsulosin-d4
Tamsulosin-d₄ ((R)-(-)-YM12617 (free base)-d₄) is deuterium labeled Tamsulosin. Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of α₁-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models .

HY-B0192S3

Alfuzosin-d6
Alfuzosin-d₆ (SL 77499-d₆) is deuterium labeled Alfuzosin. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .

HY-B0192S3A

Alfuzosin hydrochloride-d6

Alfuzosin (hydrochloride)-d₆ (SL 77499-10-d₆) is deuterium labeled Alfuzosin (hydrochloride). Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .

HY-13635S

Finasteride-d9

Finasteride-d₉ is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC₅₀ of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .

HY-B0391S1

Naftopidil-d5
Naftopidil-d₅ is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia .

HY-B0391S2

Naftopidil-d7
Naftopidil-d₇ (KT-611-d₇ ) is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Prostate+Hyperplasia

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products